Getting smarter - The toxicity of undertreated HIV infection

New England Journal of Medicine

Volumn 355, Issue 22, 2006, Pages 2359-2361

  Currier, Judith S ^a   Baden, Lindsey R ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTINUOUS INFUSION; DISEASE COURSE; DRUG INTERMITTENT THERAPY; EDITORIAL; ESOPHAGUS CANDIDIASIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY DISEASE; LIVER DISEASE; MORTALITY; OPEN STUDY; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS REPLICATION;

ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; HIV INFECTIONS; HUMANS;

EID: 33751510680     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe068250     Document Type: Editorial

References (12)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60.
2. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003;349:1993-2003. [Erratum, N Engl J Med 2004;350:955.]
3. Periard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors: the Swiss HIV Cohort Study. Circulation 1999;100:700-5.
4. Hammer SM. Management of newly diagnosed HIV infection. N Engl J Med 2005;353:1702-10.
5. Krolewiecki AJ, Zala C, Vanzulli C, et al. Safe treatment interruptions in patients with nadir CD4 counts of more than 350 cells/microL: a randomized trial. J Acquir Immune Defic Syndr 2006;41:425-9.
6. Ananworanich J, Gayet-Ageron A, Le Braz M, et al. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. Lancet 2006;368:459-65.
7. Tarwater PM, Parish M, Gallant JE. Prolonged treatment interruption after immunologic response to highly active antiretroviral therapy. Clin Infect Dis 2003;37:1541-8.
8. Pai NP, Tulsky JP, Lawrence J, Colford JM Jr, Reingold AL. Structured treatment interruptions (STI) in chronic suppressed HIV infection in adults. Cochrane Database Syst Rev 2005;4:CD005482.
9. The SMART Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006;355:2283-96.
10. Williams PL, Currier JS, Swindells S. Joint effects of HIV-1 RNA levels and CD4 lymphocyte cells on the risk of specific opportunistic infections. AIDS 1999;13:1035-44.
11. Wolf K, Tsakiris DA, Weber R, Erb P, Battegay M. Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1. J Infect Dis 2002;185:456-62.
12. Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006;296:827-43.